RT Journal Article
SR Electronic
T1 Integrated Genomic Surveillance reveals extensive onward transmission of travel-imported SARS-CoV-2 infections in the community
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.18.21264530
DO 10.1101/2021.10.18.21264530
A1 Houwaart, Torsten
A1 Belhaj, Samir
A1 Tawalbeh, Emran
A1 Nagels, Dirk
A1 Finzer, Patrick
A1 Fröhlich, Yara
A1 Benmoumene, Assia
A1 Asskali, Dounia
A1 Haidar, Hussein
A1 von Dahlen, Janina
A1 Nicolai, Jessica
A1 Stiller, Lisa
A1 Blum, Jacqueline
A1 Lange, Christian
A1 Adelmann, Carla
A1 Schroer, Britta
A1 Osmers, Ute
A1 Grice, Christiane
A1 Kirfel, Phillipp P.
A1 Jomaa, Hassan
A1 Strelow, Daniel
A1 Hülse, Lisanna
A1 Pigulla, Moritz
A1 Kreuzer, Pascal
A1 Tyshaieva, Alona
A1 Weber, Jonas
A1 Wienemann, Tobias
A1 Vasconcelos, Malte Kohns
A1 Hoffmann, Katrin
A1 Lübke, Nadine
A1 Hauka, Sandra
A1 Andree, Marcel
A1 Jürgen Scholz, Claus
A1 Jazmati, Nathalie
A1 Göbels, Klaus
A1 Zotz, Rainer
A1 Pfeffer, Klaus
A1 Timm, Jörg
A1 Ehlkes, Lutz
A1 Walker, Andreas
A1 Dilthey, Alexander T.
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/10/26/2021.10.18.21264530.abstract
AB Integration of genomic surveillance with contact tracing provides a powerful tool for the reconstruction of person-to-person pathogen transmission chains. We report two large clusters of SARS-CoV-2 cases (“Delta” clade, 110 cases combined) detected in July 2021 by Integrated Genomic Surveillance in Düsseldorf. Structured interviews and deep contact tracing demonstrated an association to a single SARS-CoV-2 infected return traveller (Cluster 1) and to return travel from Catalonia and other European countries (Cluster 2), highlighting the importance of containing travel-imported SARS-CoV-2 infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Ministry for Work, Health and Social Affairs of the State of North Rhine-Westphalia; the Jürgen Manchot Foundation; the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung; award numbers 031L0184B and 01KX2021); the German Research Foundation (award 428994620).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our study was IRB-approved by the ethics committee of the Heinrich Heine University Düsseldorf (#2020-839).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFASTA files and the phylogenetic tree of all Düsseldorf and Solingen samples have been made available via OSF (DOI 10.17605/OSF.IO/B7TU3). All viral genome assemblies from Düsseldorf surveillance samples that meet GISAID quality criteria have also been submitted to GISAID. Accessions are listed in Supplementary Table 1. https://osf.io/b7tu3/ https://www.gisaid.org/